Full-Time

Director – Quality Assurance

Drug Substance

Confirmed live in the last 24 hours

Pliant Therapeutics

Pliant Therapeutics

51-200 employees

Develops treatments for fibrotic diseases

Biotechnology
Healthcare

Compensation Overview

$225k - $235kAnnually

Senior, Expert

San Bruno, CA, USA

Hybrid position requiring 3 days/week at Pliant in South San Francisco.

Category
QA & Testing
Quality Assurance
Requirements
  • 12+ years’ experience required with a BS/BA degree in a scientific discipline or 10+ years’ experience with a MS degree.
  • At least 10+ years of pharmaceutical or biotechnology industry cGMP experience including 5+ years of experience in positions of management responsibility within Quality Assurance.
  • Strong knowledge of cGMP, ICH, FDA, and EU regulations.
  • Direct experience working with CSPs within the US and globally to meet disposition timelines.
  • Prior global commercial experience, including process validation and technology transfer.
  • Exercise sound judgement in ensuring that written procedures are followed with proven ability to drive quality process improvement initiatives.
  • Highly collaborative team player who fosters open communication and facilitates cooperation between stakeholders.
  • Excellent written and oral communication skills with the demonstrated ability to communicate with internal and external team members clearly and concisely.
  • Strong technical acumen with proven leadership capabilities and prior experience leading direct reports.
  • Available to travel domestically and internationally when needed.
  • Small company / pre-commercial to commercialization stage experience.
  • Small molecule and solid dosage experience. Biologics experience is a plus.
  • Applies a solutions-oriented mindset and approach to resolving complex quality issues.
  • Effective strategic leader and ability to mentor and develop team members.
  • High self-awareness and commitment to iterative learning and development.
  • Strong analytical, problem-solving, and decision-making capabilities.
  • Must demonstrate high organizational, prioritization and management proficiencies.
Responsibilities
  • Responsible for the disposition of drug substance, including review of master and executed batch records, specifications, certificates of analysis and analytical test data (in-process and release) for manufacturing and testing conducted at CSPs.
  • Review and approve validation protocols/reports (e.g., process, method), analytical test methods, reference standard, stability protocols/reports and establishment of retest date.
  • Support commercialization activities, including process validation and technology transfer.
  • Support the development, implementation, and enhancement of Quality Systems including disposition, vendor management, deviations, change control and CAPA.
  • Perform review and closure of internal and CSP generated deviations (including OOS and OOT), change controls, and CAPAs, ensuring timely escalation and notification to leadership and compliant resolution of product-impacting quality issues.
  • Establish and ensure adherence to batch-related metrics, effectively communicate status, and provide strategic recommendations and improvement actions to Senior Management.
  • Participate in Quality Management meetings such as Material Review Board and Quality Management Review.
  • Contribute to development and revision of Quality Agreements.
  • Collaborate on supplier qualification and management including supplier audits, as needed.
  • Participate in internal and external inspection readiness and inspection activities.
  • Contribute to CMC sections of regulatory submissions as necessary.
  • Build and foster a quality mindset within Quality and throughout the company by ensuring consistent, risk-based process are employed in decision making.

Pliant Therapeutics develops treatments for fibrotic diseases, which cause thickening and scarring of connective tissue, leading to organ dysfunction. Their products work by targeting the biological mechanisms behind fibrosis, particularly through the inhibition of integrins, proteins that help cells stick together and communicate. This focus allows Pliant to create specific and effective therapies for various fibrotic conditions. Unlike many competitors, Pliant emphasizes a deep understanding of fibrosis and integrin biology, which informs their drug development process. The company's goal is to stop the progression of fibrotic diseases and restore normal organ function, ultimately improving the lives of patients affected by these conditions.

Company Stage

IPO

Total Funding

$201.4M

Headquarters

San Francisco, California

Founded

2015

Growth & Insights
Headcount

6 month growth

6%

1 year growth

12%

2 year growth

49%
Simplify Jobs

Simplify's Take

What believers are saying

  • Pliant's accelerated development of bexotegrast for IPF and positive Phase 2a trial results indicate strong potential for successful market entry.
  • The company's participation in high-profile investor events and scientific congresses enhances its visibility and credibility in the biotech community.
  • Recent strategic appointments, including a new Chief Development Officer and Chief Regulatory Officer, bolster Pliant's leadership team and operational capabilities.

What critics are saying

  • The high costs and long timelines associated with drug development pose financial risks, especially if clinical trials do not meet endpoints.
  • The competitive landscape in biopharmaceuticals, particularly in fibrosis treatment, requires Pliant to continuously innovate to maintain its edge.

What makes Pliant Therapeutics unique

  • Pliant Therapeutics focuses specifically on fibrotic diseases, leveraging deep expertise in fibrosis and integrin biology, unlike competitors with broader therapeutic areas.
  • Their targeted approach to integrin inhibition offers a unique mechanism of action that sets them apart from other fibrosis treatments.
  • Pliant's commitment to rigorous clinical trials and data-driven development ensures high standards of efficacy and safety, distinguishing them in the biopharmaceutical market.

Help us improve and share your feedback! Did you find this helpful?